Clinical trials suggest that afatinib is active in NSCLC tumors harboring specific uncommon EGFR mutations, which include Leu861Gln, Gly719Xaa and Ser768Ile [89]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.